Cizzle Biotechnology: Strategic alliance in China

Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test, to be used alongside a positive chest scan, that allows early detection of lung cancer. This should result in a significant reduction in the number of false positives, reduce the number of scans and improve patient outcomes. Cizzle has converted a memorandum of understanding (MoU) with partners in China into a full strategic alliance for the development and commercialisation of its lung cancer test in China.

  • Strategy: Cizzle Biotechnology is a diagnostic company that is progressing a biomarker diagnostic assay, which aims to deliver a simple blood test for lung cancer that can pick up the disease earlier to improve the chances of survival, and to greatly reduce the need for unnecessary follow-up tests and tissue biopsies.
  • MoU: In November 2021, Cizzle announced an MoU with the International Co-Innovation Centre for Advanced Medical Technology (iCCAMT) and Shenzhen Intelliphecy Life Technologies Co., Ltd. (Intelliphecy) for the development and commercialisation of its CIZ1b-based early lung cancer biomarker test in China.
  • Full agreement: Cizzle has converted this MoU into a full commercial deal. The partners will be responsible for all development, manufacturing, regulatory and commercial activities in China. Cizzle will be paid for the supply of antibodies and reagents used in the test, and will receive a royalty of 10% on net sales.
  • Risks: Cizzle is a small company with a single asset and limited resources. Portfolio expansion through partnerships and royalty agreements has expanded its income opportunities and reduced risk, but future success is dependent on additional partnerships and out-licensing deals being signed.
  • Investment summary: Since listing, Cizzle Biotechnology has delivered a reasonable stream of news, particularly with collaborations and strategic partnerships that accelerate the number and magnitude of potential income streams. Despite this, the shares have underperformed, leaving the company trading on an EV of just £6.3m. Key to changing investor sentiment will be delivery of the monoclonal antibodies needed for the commercial test, which will also trigger the development in China.
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to